S&P 500 For 2016 And Beyond: Lessons From The Past To Guide Your Portfolio

Over the past year and a half, there is no doubt that some investment banks, research firms, money managers and other bears alike have been waving the red flag as to the inevitable crash of the global economy, predicting not only lower than average future returns but impending doom. Their claims come from the usual data points: S&P 500 profits are down, S&P 500 P/E ratio at decade highs, a slowing Chinese economy, a weak transportation index, the steadiness of housing starts, US GDP barely growing at inflation, the end of the commodity super cycle, and, of course, the usual cop out of “these strong returns realized by the market over the last 2 years are not sustainable because they are propped up by a Fed bubble”. Oh, and let’s not forget “watch what the bond markets are telling us”, the usual cliché posed by some managers and analysts as if they are the next boy who cried wolf predicting the come of the ‘Great Recession, Part 2’.

To continue reading please visit Seeking Alpha.

Herman Miller, Inc.: More Upside To Come

 

If I were to ask you to name me a company growing earnings at 500% year-over-year, return on invested capital at +16%, EPS growth quarter-over-quarter of +33% and ROE at +25%, which company would you choose?

I previously posed a similar question with impressive metrics in a previous article seen here, and the answer to this question was none other than good ol’ boring Unilever (NYSE:UL). In this case, many of you might guess a high flying technology company or biopharmaceutical company but the owner of these impressive metrics is none other than Herman Miller Inc. (NASDAQ: MLHR): a global provider of office furniture and fixtures for educational, commercial and healthcare providers.

To continue reading please visit Seeking Alpha.

Disclosure: Logos LP has no position in MLHR.

Global Brass And Copper Holdings: Take Advantage Of Effective Capital Management

Global Brass and Copper Holdings (NYSE:BRSS) is a global supplier, distributor and fabricator of copper and brass products, including a range of sheet, strip, foil, rod, tube and fabricated metal component products. The company should be seen as a short-term trade: investing in commodity-linked businesses with narrow margins and moats is not the kind of investment I like to see overall. However, there are some interesting catalysts, metrics and technical indicators which make BRSS a short-term buy.

BRSS has been a small-cap market darling for some time and with good reason. Overall, the main argument for going long on BRSS is not betting on the rise in copper (which, if that were the case, would certainly propel the stock), but rather focusing on its ability to manage working capital above and beyond its competitors or any other industry.

To continue reading please visit Seeking Alpha.

Disclosure: Logos LP has no position in BRSS.

Manhattan Associates: Our Top Mid-Cap Tech Pick

 

Manhattan Associates (NASDAQ: MANH) is a mid-cap provider of supply-chain, Omni-channel and inventory software to wholesalers, manufacturers and logistics providers worldwide. As stated in the company’s tear sheet, the company supply-chain solutions have been “architected to eliminate silos between warehousing and transportation” while its Omni-channel and inventory solutions allow organizations to “provide the infrastructure retailers need” and “manage forecasting, budgeting and planning”. The company has had an incredible run over the last little while (up 82% YTD – Figure 1) and by all traditional metrics seems expensive (very high PE ratio, high price to book, high price to cash flow) but I believe there is still room to run for this stock.

To continue reading please visit Seeking Alpha.

Disclosure: Logos LP has no position in MANH.

GlaxoSmithKline: Unfairly Beaten Given Strategic Direction

 

GlaxoSmithKline PLC (NYSE: GSK) is a global pharmaceutical giant that is trading below intrinsic value. The company’s real focus is on scale and innovation – providing much of the world with the drugs and medications it needs while containing an expansive list of patent-protected drugs in late stage development. Over 59% of the company’s revenues is based on prescription drugs while vaccines and consumer drugs make up 16% and 25%, respectively. The company is forecasting mid-single digit growth for all groups with earnings from 2016-2020 to hit high single digit CAGR.

To continue reading please visit Seeking Alpha.

Disclosure: Logos LP has no position in GSK.